Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Pfizer said it's developing a once-daily GLP-1 weight loss pill. In postmenopausal women with osteoporosis, romosozumab ...

Pfizer Inc. announced on Thursday that it will move forward with the testing of its modified version of the once-daily weight ...

Investors with a lot of money to spend have taken a bullish stance on Pfizer PFE. And retail traders should know. We noticed ...

Pfizer inadvertently gave a leg up to two obesity biotechs yesterday with the announcement that an extended-release ...

Pfizer has dragged the oral GLP-1 candidate danuglipron back from the brink. Months after dropping one version of the asset, ...

Pfizer announced that it has selected its preferred once-daily modified release formulation of danuglipron, a move that is ...

Pfizer Inc. is moving forward with a weight-loss pill as it seeks to mount a comeback from its post-pandemic slump, but the ...

Pfizer is looking to challenge leaders Eli Lilly and Novo Nordisk in the fast-growing market for weight loss drugs. Pfizer ...

Pfizer has selected its preferred once-daily modified release formulation for danuglipron, an oral GLP-1 receptor agonist, ...

Pfizer plans to move a reworked, once-a-day version of its weight-loss pill danuglipron into clinical trials later this year, ...

Pfizer said it saw “encouraging” data from an ongoing early stage trial of its oral weight loss drug, danuglipron.